GSK Lamictal Prices Don't Breach Deal, Judge Says

Law360, New York (June 17, 2009, 12:00 AM EDT) -- A federal judge has thrown out a suit alleging that GlaxoSmithKline PLC's effort to sell its Lamictal epilepsy drug at generic prices breached a license agreement giving Teva Pharmaceutical Industries Ltd. exclusive rights to manufacture and sell a generic version of the drug.

Judge Dennis M. Cavanaugh of the U.S. District Court for the District of New Jersey on Tuesday dismissed both of Teva's breach of contract claims, ruling that GSK had the right to sell Lamictal at whatever prices it chose.

GSK originally filed a...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.